raav.hcnga3
Gene therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02610582)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclic nucleotide-gated cation channel alpha-3Supplementation
supplementation - CNGA3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raav.hcnga3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03758404 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2019 | MeiraGTx |
| NCT03278873 | Phase 1/Phase 2 (Phase 2) | Jun 27, 2017 | Emas Pharma Ltd., MeiraGTx, Syne Qua Non Limited |
| NCT03001310 | Phase 1/Phase 2 (Phase 2) | Jan 16, 2017 | MeiraGTx |
| NCT02610582 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Ludwig Maximilians University, STZ eyetrial, University of Tuebingen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MeiraGTx | For profit | 3 | 3 | 1 | 2017 |
| Emas Pharma Ltd. | For profit | 1 | 0 | 1 | 2017 |
| Ludwig Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| STZ eyetrial | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Syne Qua Non Limited | For profit | 1 | 0 | 1 | 2017 |
| University of Tuebingen | Academic/Hospital | 1 | 0 | 1 | 2015 |
6 organizations
Page 1 / 1